(Q42627821)

English

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

scientific article published on 11 November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kazuhiro Yoshida

6

object named as

Kazuhiro Yoshida

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

author name string

Yasuhide Yamada

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Daisuke Takahari

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hiroshi Matsumoto

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hideo Baba

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Masato Nakamura

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Motoki Yoshida

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Shigeyoshi Iwamoto

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Ken Shimada

9

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Yoshito Komatsu

10

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Yasutsuna Sasaki

11

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Taroh Satoh

12

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Keiichi Takahashi

13

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Hideyuki Mishima

14

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Kei Muro

15

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Masahiko Watanabe

16

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Yuh Sakata

17

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Satoshi Morita

18

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Yasuhiro Shimada

19

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Kenichi Sugihara

20

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

11 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1278-1286

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Median follow-up in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970490-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70490-X

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42627821&oldid=1963373856"